Peer-reviewed veterinary case report
Celecoxib slows growth of canine mammary tumor cells without COX-2
By Tamura, Dai et al.·Published in International journal of oncology·2015·Nihon University College of Bioresource Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms.
- Species:
- dog
Plain-English summary
A study found that celecoxib, a medication commonly used for pain relief, may also help treat mammary tumors in dogs. In tests with canine mammary tumor cells, celecoxib was shown to slow down cell growth and promote cell death through various mechanisms, even in cases where a specific protein (COX-2) was not present. This suggests that celecoxib could be a promising option for treating mammary tumors in dogs, potentially in combination with other cancer treatments.
People also search for: dog mammary tumor treatment · celecoxib for dogs · canine cancer medication
Abstract
Celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers. The aim of this study was to clarify the mechanism of action of celecoxib in canine mammary tumors. We examined the antitumor effects of celecoxib in AZACB canine mammary tumor cells expressing low levels of cyclooxygenase‑2 (COX‑2) to minimize the effect of COX‑2 on its activity. Our data revealed that celecoxib inhibited cell proliferation mainly via COX‑2‑independent mechanisms. Specifically, celecoxib decreased the proportion of cells in S phase and increased G2/M arrest, which was associated with increased expression of the cyclin‑dependent kinase inhibitors (CDKIs) p21 and p27. In addition, treatment with celecoxib downregulated COX‑2 expression, and induced apoptosis via both the intrinsic and extrinsic pathways. These findings suggest that celecoxib might be a useful agent for the treatment of canine mammary tumors, regardless of COX‑2 expression. In the future, it might be possible to use a combination of celecoxib and other antitumor agents to treat canine mammary tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25571853/